Ultimovacs Past Earnings Performance
Past criteria checks 0/6
Ultimovacs's earnings have been declining at an average annual rate of -22.7%, while the Biotechs industry saw earnings growing at 15.7% annually.
Key information
-22.7%
Earnings growth rate
-13.2%
EPS growth rate
Biotechs Industry Growth | 20.9% |
Revenue growth rate | n/a |
Return on equity | -68.6% |
Net Margin | n/a |
Next Earnings Update | 21 Aug 2024 |
Recent past performance updates
Recent updates
Companies Like Ultimovacs (OB:ULTI) Can Afford To Invest In Growth
Feb 21Ultimovacs (OB:ULTI) Is In A Strong Position To Grow Its Business
Oct 26Companies Like Ultimovacs (OB:ULTI) Are In A Position To Invest In Growth
Oct 05Ultimovacs (OB:ULTI) Is In A Good Position To Deliver On Growth Plans
May 19Here's Why We're Not At All Concerned With Ultimovacs' (OB:ULTI) Cash Burn Situation
Jul 27We're Hopeful That Ultimovacs (OB:ULTI) Will Use Its Cash Wisely
Mar 23Have Insiders Sold Ultimovacs ASA (OB:ULTI) Shares Recently?
Feb 13Revenue & Expenses Breakdown
How Ultimovacs makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 0 | -178 | 38 | 0 |
31 Dec 23 | 0 | -189 | 61 | 0 |
30 Sep 23 | 0 | -204 | 59 | 0 |
30 Jun 23 | 0 | -186 | 57 | 0 |
31 Mar 23 | 0 | -165 | 59 | 0 |
31 Dec 22 | 0 | -168 | 57 | 0 |
30 Sep 22 | 0 | -148 | 58 | 0 |
30 Jun 22 | 0 | -153 | 54 | 0 |
31 Mar 22 | 0 | -168 | 51 | 0 |
31 Dec 21 | 0 | -165 | 47 | 0 |
30 Sep 21 | 0 | -138 | 47 | 0 |
30 Jun 21 | 0 | -126 | 46 | 0 |
31 Mar 21 | 0 | -124 | 49 | 0 |
31 Dec 20 | 0 | -121 | 46 | 0 |
30 Sep 20 | 0 | -121 | 39 | 0 |
30 Jun 20 | 0 | -108 | 39 | 0 |
31 Mar 20 | 0 | -77 | 19 | 0 |
31 Dec 19 | 0 | -61 | 17 | 0 |
30 Sep 19 | 0 | -48 | 15 | 0 |
30 Jun 19 | 0 | -48 | 16 | 0 |
31 Mar 19 | 0 | -59 | 25 | 0 |
31 Dec 18 | 0 | -55 | 24 | 0 |
30 Sep 18 | 0 | -50 | 23 | 0 |
30 Jun 18 | 0 | -42 | 18 | 0 |
31 Mar 18 | 0 | -35 | 17 | 0 |
31 Dec 17 | 0 | -33 | 17 | 0 |
31 Dec 16 | 0 | -29 | 13 | 0 |
Quality Earnings: ULTI is currently unprofitable.
Growing Profit Margin: ULTI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ULTI is unprofitable, and losses have increased over the past 5 years at a rate of 22.7% per year.
Accelerating Growth: Unable to compare ULTI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ULTI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (3%).
Return on Equity
High ROE: ULTI has a negative Return on Equity (-68.63%), as it is currently unprofitable.